Cimerli™ (ranibizumab-eqrn) was FDA approved on August 2, 2022 as interchangeable with Lucentis ® (ranibizumab). Cimerli is the third interchangeable biosimilar approved in the US, following Semglee ® ...

Sgt. Zach Smola, rear door gunner on a CH-47, keeps watch on the mountains in Uruzgan province, Afghanistan, May 12, 2013. The Chinooks, operated by members of Bravo Company, 2nd Battalion, 104th ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press ...

Biologics have revolutionized the management of immune-mediated inflammatory diseases (IMIDs). Biosimilars are biologics that exhibit no significant differences in safety or efficacy compared with ...

Please provide your email address to receive an email when new articles are posted on . Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co.), a HER2 receptor antagonist and biosimilar to ...

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician. An interchangeable designation means that the product, ...

An interchangeable product can be expected to produce the same clinical result as the reference product in any given patient. Yesafili and Opuviz are both vascular endothelial growth factor (VEGF) ...